Compare GKOS & ADC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | ADC |
|---|---|---|
| Founded | 1998 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.0B |
| IPO Year | 2015 | 1996 |
| Metric | GKOS | ADC |
|---|---|---|
| Price | $238.12 | $70.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 20 |
| Target Price | ★ $243.85 | $77.86 |
| AVG Volume (30 Days) | ★ 1.5M | 1.4M |
| Earning Date | 10-28-2026 | 10-20-2026 |
| Dividend Yield | N/A | ★ 4.63% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.47 |
| Revenue | $507,442,000.00 | ★ $718,398,000.00 |
| Revenue This Year | $53.82 | $16.93 |
| Revenue Next Year | $28.56 | $12.82 |
| P/E Ratio | ★ N/A | $47.32 |
| Revenue Growth | ★ 32.33 | 16.42 |
| 52 Week Low | $93.78 | $64.34 |
| 52 Week High | $255.19 | $82.08 |
| Indicator | GKOS | ADC |
|---|---|---|
| Relative Strength Index (RSI) | 59.90 | 58.33 |
| Support Level | $147.72 | $64.38 |
| Resistance Level | $255.19 | $70.91 |
| Average True Range (ATR) | 11.84 | 1.15 |
| MACD | -1.49 | 0.09 |
| Stochastic Oscillator | 43.31 | 77.85 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.